About Averna Therapeutics
Avenna Therapeutics (AvernaTx) is a biotechnology company developing targeted small-molecule therapies for neurodegenerative diseases, including Alzheimer’s. Their approach focuses on restoring neuronal function by modulating brain cell metabolism and signaling pathways.
Open positions (1)
Company details
Funding
Total raised
$82M
Last stage
Series A
Investors
Founders
Roy Amariglio
Formerly a researcher at the Weizmann Institute of Science and an executive at Bayer; later an investor at OrbiMed. Identified the scientific opportunity that led to founding the company (then called Exsilio Therapeutics).
Thomas M. Barnes
Appointed CEO in January 2025. Previously CEO of Orna Therapeutics and CSO/founding team member at Intellia Therapeutics. Holds a doctorate from the University of Cambridge.
Tal Zaks
Former Chief Medical Officer at Moderna, where he led development of the COVID-19 vaccine. Joined Averna/Exsilio as Executive Chairman and Interim CEO, helping raise the Series A round.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.